Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Co-administering BBIBP-CorV with Influenza or Pneumococcal Vaccines
NCT04790851Phase 4Completed
- Sponsor
- China National Biotec Group
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by China National Biotec Group. Primary endpoints: Seroconversion rate for SARS-CoV-2 antibodies, Neutralizing antibody level against SARS-CoV-2 and 5 more. Started Mar 2021; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04790851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790851.